Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18880325 | DRUG INJECTION DEVICE | December 2024 | December 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 17901816 | INDWELLING CATHETER, MEDICAL VALVE, AND CATHETER ASSEMBLY | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17764421 | Injection Device with an End-of-Dose Indicator | March 2022 | November 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17588668 | LUER LOCK INTRAVENOUS CONNECTOR | January 2022 | January 2026 | Abandon | 47 | 5 | 0 | No | No |
| 17587824 | AUTOINJECTOR | January 2022 | June 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17586745 | INJECTION GUIDANCE TEMPLATE | January 2022 | June 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17620982 | RETRACTABLE NEEDLE WITH DAMPING | December 2021 | August 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17618899 | INFUSION DEVICE | December 2021 | March 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17612409 | Method for Determining Syringe Parameters by a Syringe Pump, and Apparatuses | November 2021 | September 2025 | Allow | 46 | 1 | 0 | Yes | No |
| 17612076 | DRIVE MECHANISM FOR A MEDICAMENT DELIVERY DEVICE | November 2021 | May 2025 | Allow | 41 | 1 | 0 | No | No |
| 17611821 | ASSEMBLY FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE | November 2021 | August 2025 | Allow | 45 | 2 | 0 | No | No |
| 17602777 | CONTROL OF BALLOON SIZE IN BOWEL IRRIGATION SYSTEM | October 2021 | July 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17487093 | LIQUID MEDICINE ADMINISTRATION DEVICE | September 2021 | January 2025 | Allow | 39 | 1 | 0 | No | No |
| 17476925 | METHODS AND DEVICES FOR ACTUATING A CLEARANCE DEVICE FOR CLEARING OBSTRUCTIONS FROM MEDICAL TUBES | September 2021 | December 2025 | Abandon | 51 | 2 | 0 | No | Yes |
| 17471103 | PAINLESS SYRINGE TO REDUCE THE NOISE AND FRICTION GENERATED WHEN PERFORATING THE ALVEOLAR BONE | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17437184 | DEVICE FOR SKIN CARE, COSMETICS, AND MEDICAL TREATMENT | September 2021 | May 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17465467 | CATHETER ASSEMBLY | September 2021 | January 2026 | Abandon | 52 | 3 | 0 | Yes | No |
| 17408699 | TRANSDERMAL DELIVERY OF HIGH VISCOSITY BIOACTIVE AGENTS | August 2021 | February 2025 | Allow | 42 | 1 | 1 | No | No |
| 17426267 | VASCULAR CATHETER AND METHOD | July 2021 | November 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17425514 | DEVICE, METHOD, AND TUBE DEVICE FOR DELIVERY OF INFUSATE FOR HUMANS | July 2021 | April 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17364156 | SYSTEM AND METHOD FOR DETECTING VENOUS NEEDLE DISLODGEMENT | June 2021 | February 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17294237 | AUTOINJECTOR | May 2021 | January 2025 | Allow | 44 | 2 | 0 | No | No |
| 17291171 | DEVICE FOR CLEANING LIQUID FROM AN EYE OF A SUBJECT | May 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17306174 | PHOTOOXIDATIVE INACTIVATION OF PATHOGENS INCLUDING SARS-CoV-2 | May 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17289439 | SYRINGE ACCESSORY DEVICE AND METHODS OF USE | April 2021 | October 2024 | Abandon | 41 | 1 | 0 | Yes | No |
| 17289371 | Medical Injection System | April 2021 | January 2026 | Allow | 57 | 4 | 0 | Yes | No |
| 17282263 | DETECTION ASSEMBLIES FOR INFUSION PUMPS | April 2021 | July 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17282245 | DRUG DELIVERY DEVICE | April 2021 | August 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17279642 | A HAND-HELD, DIRECTIONAL, MULTI- FREQUENCY PROBE FOR SPINAL NEEDLE PLACEMENT | March 2021 | August 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17278870 | DEVICE FOR GENERATING COLD PLASMA COMPRISING ELECTRODES AND DIELECTRICS | March 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17262002 | AUTOMATIC INJECTOR FOR STANDARD MEDICAL SYRINGES | January 2021 | December 2024 | Abandon | 47 | 2 | 0 | No | No |
| 16816412 | PLATFORM FOR DELIVERING SECUREMENT DEVICE | March 2020 | September 2025 | Allow | 60 | 6 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DIPERT, FORREST BLAKE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DIPERT, FORREST BLAKE works in Art Unit 3783 and has examined 26 patent applications in our dataset. With an allowance rate of 42.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner DIPERT, FORREST BLAKE's allowance rate of 42.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DIPERT, FORREST BLAKE receive 1.69 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by DIPERT, FORREST BLAKE is 44 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +47.2% benefit to allowance rate for applications examined by DIPERT, FORREST BLAKE. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.0% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 23% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 7% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.